Saudi Chemical Holding Valuation
Is 2230 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2230 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 2230 (SAR10) is trading above our estimate of fair value (SAR0.03)
Significantly Below Fair Value: 2230 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2230?
Key metric: As 2230 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 2230's PE Ratio? | |
|---|---|
| PE Ratio | 25.9x |
| Earnings | ر.س326.16m |
| Market Cap | ر.س8.43b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.6x |
| Enterprise Value/EBITDA | 18.8x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 2230's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 17.3x | ||
9527 Alf Meem Yaa for Medical Supplies and Equipment | 17.6x | n/a | ر.س666.4m |
9530 Arabian International Healthcare Holding | 25.2x | n/a | ر.س750.0m |
9600 Qomel | 15.4x | n/a | ر.س360.5m |
9574 Professional Medical Expertise | 10.9x | n/a | ر.س302.4m |
2230 Saudi Chemical Holding | 25.9x | n/a | ر.س8.4b |
Price-To-Earnings vs Peers: 2230 is expensive based on its Price-To-Earnings Ratio (25.9x) compared to the peer average (17.3x).
Price to Earnings Ratio vs Industry
How does 2230's PE Ratio compare vs other companies in the Asian Healthcare Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 2230 is expensive based on its Price-To-Earnings Ratio (25.9x) compared to the Asian Healthcare industry average (21x).
Price to Earnings Ratio vs Fair Ratio
What is 2230's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 25.9x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 2230's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.